89bio price target raised to $34 from $30 at BofA

BofA raised the firm’s price target on 89bio (ETNB) to $34 from $30 and keeps a Buy rating on the shares. Akero Therapeutics’ (AKRO) 96-week update of its SYMMETRY phase 2b trial of efruxifermin in patients with cirrhosis due to metabolic disease was “impressive” and “transformative,” says the analyst, who notes that shares of Akero and rival FGF21 developer 89bio are up “meaningfully” since Monday. After having hosted a call with a hepatologist key opinion leader, the firm characterizes his impressions as very positive after describing the results as “game-changing,” the analyst added.